TY - JOUR
T1 - Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx velocity balloon-expandable stent (RAVEL)
T2 - Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size
AU - Regar, E.
AU - Serruys, P. W.
AU - Bode, C.
AU - Holubarsch, C.
AU - Guermonprez, J. L.
AU - Wijns, W.
AU - Bartorelli, A.
AU - Constantini, C.
AU - Degertekin, M.
AU - Tanabe, K.
AU - Disco, C.
AU - Wuelfert, E.
AU - Morice, M. C.
PY - 2002/10/8
Y1 - 2002/10/8
N2 - Background - Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, the amount of neointimal tissue is disproportionately greater than the vessel caliber, resulting in higher restenosis rates. In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, ≈40% of the vessels were small (2.84 mm). At 6-month follow-up, the restenosis rate in the SES group was 0% in all strata (versus 35%, 26%, and 20%, respectively, in the BS group). In-stent late loss was 0.01±0.25 versus 0.80±0.43 mm in stratum I, 0.01±0.38 versus 0.88±0.57 mm in stratum II, and -0.06±0.35 versus 0.74±0.57 mm in stratum III (SES versus BS). In SES, the minimal lumen diameter (MLD) remained unchanged (Δ -0.72 to 0.72 mm) in 97% of the lesions and increased (=late gain, ΔMLD
AB - Background - Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, the amount of neointimal tissue is disproportionately greater than the vessel caliber, resulting in higher restenosis rates. In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, ≈40% of the vessels were small (2.84 mm). At 6-month follow-up, the restenosis rate in the SES group was 0% in all strata (versus 35%, 26%, and 20%, respectively, in the BS group). In-stent late loss was 0.01±0.25 versus 0.80±0.43 mm in stratum I, 0.01±0.38 versus 0.88±0.57 mm in stratum II, and -0.06±0.35 versus 0.74±0.57 mm in stratum III (SES versus BS). In SES, the minimal lumen diameter (MLD) remained unchanged (Δ -0.72 to 0.72 mm) in 97% of the lesions and increased (=late gain, ΔMLD
KW - Angioplasty
KW - Drugs
KW - Restenosis
KW - Stents
UR - http://www.scopus.com/inward/record.url?scp=0037044449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037044449&partnerID=8YFLogxK
U2 - 10.1161/01.CIR.0000034045.36219.12
DO - 10.1161/01.CIR.0000034045.36219.12
M3 - Article
C2 - 12370218
AN - SCOPUS:0037044449
VL - 106
SP - 1949
EP - 1956
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 15
ER -